Research and Markets: Investigation Report on China's Imatinib Mesylate (Novartis) Market 2010-2019

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/92w985/investigation) has announced the addition of the "Investigation Report on China Imatinib Mesylate Market, 2010-2019" report to their offering.

Imatinib Mesylate was a tyrosine kinase inhibitor developed by Novartis. On May. 10, 2001, Imatinib Mesylate got FDA's express approval with the trade name of Gleevec due to its groundbreaking anti- tumor mechanism. On Dec. 23, 2009, Imatinib Mesylate gained its status as the first- line treatment for chronic myelogenous leukemia under FDA's approval. And now it has been approved for treatment of chronic myelogenous leukemia in more than 80 countries around the world.

After entering Chinese market on Apr. 17, 2002, Imatinib Mesylate has developed fast with annual sales reaching CNY 532 million in 2014 and CAGR reaching up to 42% during the period of 2005- 2014. Currently, Imatinib Mesylate in the Chinese market is made by the following three companies: Novartis (Swiss), Chia Tai Tianqing Pharmaceutical Group Co., Ltd and Hansoh Pharmaceutical, among which Novartis has the largest market share of over 98% with sales value reaching up to CNY 523 million in 2014.

Imatinib Mesylate has accurate curative effects on chronic myelogenous leukemia despite its relatively high price. Chinese patients with low incomes were once sued for purchasing Imatinib Mesylate smuggled from India whose price is only 10% or less of that in Chinese market. As China's economy develops, people's income and purchasing power increases. Since an increasing number of patients are estimated to afford Imatinib Mesylate, its market size will expand further in China.

Key Topics Covered:

1 Related Concepts of Imatinib Mesylate

2 Market Profile of Imatinib Mesylate in China

3 Survey on Sales Status of Imatinib Mesylate in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Imatinib Mesylate in China, 2010-2014

5 Survey on Dosage Forms of Imatinib Mesylate in China, 2010-2014

6 Reference Price of Imatinib Mesylate in Chinese Hospitals in 2014

7 Major Manufacturers of Imatinib Mesylate in Chinese Market, 2010-2014

8 Market Outlook of Imatinib Mesylate in China, 2015-2019

Companies Mentioned

- Chia Tai Tianqing Pharmaceutical Group Co., Ltd

- Hansoh Pharmaceutical

- Novartis

For more information visit http://www.researchandmarkets.com/research/92w985/investigation

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Chemicals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Chemicals